1. Home
  2. SMID vs KZIA Comparison

SMID vs KZIA Comparison

Compare SMID & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$28.36

Market Cap

157.6M

Sector

Industrials

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$12.57

Market Cap

154.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
KZIA
Founded
1960
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.6M
154.9M
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
SMID
KZIA
Price
$28.36
$12.57
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
11.1K
199.6K
Earning Date
04-14-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
N/A
EPS
0.25
N/A
Revenue
$93,446,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$111.64
N/A
Revenue Growth
19.03
N/A
52 Week Low
$25.60
$4.86
52 Week High
$43.62
$17.40

Technical Indicators

Market Signals
Indicator
SMID
KZIA
Relative Strength Index (RSI) 42.37 N/A
Support Level $27.61 N/A
Resistance Level $31.47 N/A
Average True Range (ATR) 1.55 0.00
MACD -0.19 0.00
Stochastic Oscillator 25.64 0.00

Price Performance

Historical Comparison
SMID
KZIA

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: